Structures by: Thennarasu S.
Total: 18
<i>N</i>-[3-Methyl-1-phenyl-1-(1<i>H</i>-tetrazol-1-yl)butan-2-yl]acetamide
C14H19N5O
IUCrData (2016) 1, 11 x161810
a=9.7056(6)Å b=7.7663(5)Å c=20.2620(9)Å
α=90° β=93.490(2)° γ=90°
C46H36N2O4
C46H36N2O4
Organic & biomolecular chemistry (2017) 15, 9 1961-1964
a=11.751(5)Å b=12.712(5)Å c=13.460(5)Å
α=89.482(5)° β=68.529(5)° γ=73.872(5)°
3a
C46H40N4O2
RSC Adv. (2015)
a=11.335(5)Å b=12.004(5)Å c=15.559(5)Å
α=106.000(5)° β=92.630(5)° γ=114.145(5)°
KSH
C49H34ClNO4
RSC Adv. (2015)
a=8.890(5)Å b=10.257(5)Å c=20.323(5)Å
α=91.701(5)° β=90.533(5)° γ=98.252(5)°
C51H38F2N4O4
C51H38F2N4O4
RSC Adv. (2015)
a=11.9700(5)Å b=15.5516(8)Å c=23.1725(11)Å
α=90° β=103.1855(19)° γ=90°
<i>N</i>-<i>tert</i>-Butyl-2-(4-methoxyphenyl)-5-methylimidazo[1,2-<i>a</i>]pyridin-3-amine
C19H23N3O
Acta Crystallographica Section E (2018) 74, 12 1913-1918
a=9.2357(7)Å b=15.6388(12)Å c=11.9840(10)Å
α=90° β=93.998(3)° γ=90°
<i>N</i>-<i>tert</i>-Butyl-2-[4-(dimethylamino)phenyl]imidazo[1,2-<i>a</i>]pyridin-3-amine
C19H24N4
Acta Crystallographica Section E (2018) 74, 12 1913-1918
a=34.9185(14)Å b=8.4656(5)Å c=11.8361(6)Å
α=90° β=91.061(5)° γ=90°
5-(1-Acetamido-3-methyl)butyl-5methyl-2,4-imidazolidinedione
C11H19N3O3,H2O1
Acta Crystallographica Section E (2001) 57, 4 o377-o379
a=6.27700(10)Å b=19.7080(4)Å c=11.93990(10)Å
α=90.00° β=101.64° γ=90.00°
Thiadiazole
C17H22N4O3S
Acta Crystallographica Section E (2008) 64, 1 o216-o216
a=18.3623(9)Å b=14.1565(7)Å c=14.1386(7)Å
α=90° β=90° γ=90°
Imidazolidinedione
C13H15N3O3
Acta Crystallographica Section C (2002) 58, 12 o715-o717
a=12.9955(9)Å b=7.7137(5)Å c=13.4699(11)Å
α=90.00° β=107.860(6)° γ=90.00°
<i>N</i>-<i>tert</i>-Butyl-2-[4-(dimethylamino)phenyl]imidazo[1,2-<i>a</i>]pyrazin-3-amine
C18H23N5
Acta Crystallographica Section E (2013) 69, 4 o612-o613
a=12.1746(11)Å b=13.9614(13)Å c=20.2985(19)Å
α=90.00° β=90.00° γ=90.00°
Ethyl 1''-benzyl-1'-methyl-2''-oxodispiro[indeno[1,2-<i>b</i>]quinoxaline-11,3'-pyrrolidine-2',3''-indoline]-4'-carboxylate
C36H30N4O3
Acta Crystallographica Section E (2013) 69, 6 o822
a=11.1927(2)Å b=11.4535(3)Å c=12.1206(3)Å
α=87.637(2)° β=86.0480(10)° γ=70.564(2)°
Ethyl 1''-benzyl-2''-oxo-2',3',5',6',7',7a'-hexahydro-1'<i>H</i>-dispiro[indeno[1,2-<i>b</i>]quinoxaline-11,2'-pyrrolizine-3',3''-indoline]-1'-carboxylate monohydrate
C38H32N4O3,H2O
Acta Crystallographica Section E (2013) 69, 6 o854-o855
a=11.0527(3)Å b=11.5834(3)Å c=12.2015(3)Å
α=97.3700(10)° β=92.0370(10)° γ=96.8100(10)°
Ethyl 8''-chloro-1'-methyl-2,12''-dioxo-12''<i>H</i>-dispiro[indoline-3,2'-pyrrolidine-3',6''-indolo[2,1-<i>b</i>]quinazoline]-4'-carboxylate
C29H23ClN4O4
Acta Crystallographica Section E (2013) 69, 7 o1062-o1063
a=8.9341(9)Å b=11.7697(12)Å c=13.3828(14)Å
α=72.776(5)° β=89.574(5)° γ=74.995(5)°
Ethyl 2-(7-oxo-3,5-diphenyl-1,4-diazepan-2-yl)acetate
C21H24N2O3
Acta Crystallographica Section E (2012) 68, 4 o1034
a=10.3721(19)Å b=20.666(4)Å c=9.1954(18)Å
α=90.00° β=104.365(5)° γ=90.00°
Ethyl 7-oxo-3,5-diphenyl-1,4-diazepane-2-carboxylate
C20H22N2O3
Acta Crystallographica Section E (2012) 68, 5 o1525-o1526
a=9.5352(3)Å b=14.8809(4)Å c=15.0800(4)Å
α=61.6500(10)° β=82.153(2)° γ=71.344(2)°
<i>N</i>-<i>tert</i>-Butyl-2-(2,6-dichlorophenyl)imidazo[1,2-a]pyrazin-3-amine
C16H16Cl2N4
Acta Crystallographica Section E (2013) 69, 6 o949-o950
a=8.1482(4)Å b=9.8553(5)Å c=11.5265(6)Å
α=93.218(2)° β=99.320(3)° γ=113.026(2)°